Published in Antiviral Res on December 04, 2006
Experimental therapies for yellow fever. Antiviral Res (2012) 0.96
Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen. Int Immunopharmacol (2008) 0.83
Modulation of Dengue virus infection in human cells by alpha, beta, and gamma interferons. J Virol (2000) 3.61
A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med (2003) 2.89
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother (2004) 1.60
Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother (2005) 1.20
Differential responses of human brain cells to West Nile virus infection. J Neurovirol (2005) 1.17
Sequential production of cytokines by dengue virus-infected human peripheral blood leukocyte cultures. J Med Virol (1999) 1.16
Interferons, interferon inducers, and interferon-ribavirin in treatment of flavivirus-induced encephalitis in mice. Antimicrob Agents Chemother (2003) 1.09
Revisiting the liver in human yellow fever: virus-induced apoptosis in hepatocytes associated with TGF-beta, TNF-alpha and NK cells activity. Virology (2005) 1.06
Macrophages and cytokines in the early defence against herpes simplex virus. Virol J (2005) 1.00
Nucleotide sequence of the NS5 gene of Banzi virus: comparison with other flaviviruses. J Gen Virol (1995) 1.00
Genetic resistance to lethal flavivirus encephalitis. I. Infection of congenic mice with Banzi virus. J Infect Dis (1976) 0.98
Comparative therapeutic efficacy of recombinant interferons-alpha, -beta, and -gamma against alphatogavirus, bunyavirus, flavivirus, and herpesvirus infections. J Interferon Res (1990) 0.98
Broad-spectrum activity of 8-chloro-7-deazaguanosine against RNA virus infections in mice and rats. Antiviral Res (1995) 0.97
Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits antitumor properties in vivo and is correlated with low intestinal tumorigenicity. Int J Cancer (2005) 0.96
Effect of cytokines on Japanese encephalitis virus production by human monocytes. Microbiol Immunol (1990) 0.94
Modulation of vaccine-induced immune responses to hepatitis C virus in rhesus macaques by altering priming before adenovirus boosting. J Infect Dis (2005) 0.92
Immunoenhancing properties and antiviral activity of 7-deazaguanosine in mice. Antimicrob Agents Chemother (1991) 0.90
Interleukin (IL)-12 receptor beta1 or IL-12 receptor beta 2 deficiency in mice indicates that IL-12 and IL-23 are not essential for host recovery from viral encephalitis. Viral Immunol (2005) 0.88
Comparative study of various immunomodulators for macrophage and natural killer cell activation and antiviral efficacy against exotic RNA viruses. Int J Immunopharmacol (1988) 0.87
Postinfection therapy of arbovirus infections in mice. Antimicrob Agents Chemother (1989) 0.82
Interleukin-2 immunotherapy and AIDS-related cytomegalovirus retinitis. Curr HIV Res (2004) 0.82
Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J Neurosci (2003) 3.50
Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection. Antimicrob Agents Chemother (2006) 2.69
In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother (2007) 2.21
Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis (2006) 1.84
Identification of active antiviral compounds against a New York isolate of West Nile virus. Antiviral Res (2002) 1.71
Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster animal models. Antivir Chem Chemother (2004) 1.60
TLR3 deletion limits mortality and disease severity due to Phlebovirus infection. J Immunol (2006) 1.50
Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother (2002) 1.49
A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res (2003) 1.43
Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Agents (2004) 1.35
Characterizing antiviral activity of adefovir dipivoxil in transgenic mice expressing hepatitis B virus. Antiviral Res (2002) 1.35
Increased blood-brain barrier permeability is not a primary determinant for lethality of West Nile virus infection in rodents. J Gen Virol (2008) 1.33
Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model. Antimicrob Agents Chemother (2007) 1.30
Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster model. Antiviral Res (2006) 1.23
Interferon alfacon-1 protects hamsters from lethal pichinde virus infection. Antimicrob Agents Chemother (2005) 1.20
Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother (2006) 1.19
Modeling hamsters for evaluating West Nile virus therapies. Antiviral Res (2004) 1.16
Combination treatment of influenza A virus infections in cell culture and in mice with the cyclopentane neuraminidase inhibitor RWJ-270201 and ribavirin. Chemotherapy (2002) 1.16
Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype. Antimicrob Agents Chemother (2006) 1.13
Activities of oseltamivir and ribavirin used alone and in combination against infections in mice with recent isolates of influenza A (H1N1) and B viruses. Antivir Chem Chemother (2006) 1.09
Error-prone replication of West Nile virus caused by ribavirin. Antiviral Res (2005) 1.08
Inhibition of severe acute respiratory syndrome-associated coronavirus (SARSCoV) by calpain inhibitors and beta-D-N4-hydroxycytidine. Antivir Chem Chemother (2004) 1.07
Protective immunity against acute phleboviral infection elicited through immunostimulatory cationic liposome-DNA complexes. Antiviral Res (2006) 1.07
Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS. J Med Chem (2006) 1.06
Characterization of antiviral activity of entecavir in transgenic mice expressing hepatitis B virus. Antiviral Res (2003) 1.05
Comparison of colorimetric, fluorometric, and visual methods for determining anti-influenza (H1N1 and H3N2) virus activities and toxicities of compounds. J Virol Methods (2002) 1.05
Characterization and treatment of cidofovir-resistant vaccinia (WR strain) virus infections in cell culture and in mice. Antivir Chem Chemother (2005) 1.05
Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int J Antimicrob Agents (2008) 1.05
Recombinant Eimeria protozoan protein elicits resistance to acute phlebovirus infection in mice but not hamsters. Antimicrob Agents Chemother (2006) 1.03
West Nile virus-induced acute flaccid paralysis is prevented by monoclonal antibody treatment when administered after infection of spinal cord neurons. J Neurovirol (2008) 1.01
Combinatorial ribavirin and interferon alfacon-1 therapy of acute arenaviral disease in hamsters. Antivir Chem Chemother (2006) 0.98
Activity of T-1106 in a hamster model of yellow Fever virus infection. Antimicrob Agents Chemother (2007) 0.98
The role of cerebellar genes in pathology of autism and schizophrenia. Cerebellum (2008) 0.97
Effect of exogenous interferon and an interferon inducer on western equine encephalitis virus disease in a hamster model. Virology (2006) 0.97
Protein from intestinal Eimeria protozoan stimulates IL-12 release from dendritic cells, exhibits antitumor properties in vivo and is correlated with low intestinal tumorigenicity. Int J Cancer (2005) 0.96
Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy (2003) 0.96
Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antiviral Res (2006) 0.94
Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J Infect Dis (2004) 0.93
Efficacy of N-methanocarbathymidine in treating mice infected intranasally with the IHD and WR strains of vaccinia virus. Antiviral Res (2007) 0.93
Anti-influenza virus activities of 4-[(1,2-dihydro-2-oxo-3H-indol-3-ylidene)amino]-N-(4,6-dimethyl-2-pyrimidin-2-yl)benzenesulphonamide and its derivatives. Antivir Chem Chemother (2006) 0.93
Enhancement of the infectivity of SARS-CoV in BALB/c mice by IMP dehydrogenase inhibitors, including ribavirin. Antiviral Res (2006) 0.92
Treatment of West Nile virus-infected mice with reactive immunoglobulin reduces fetal titers and increases dam survival. Antiviral Res (2005) 0.91
Neutralizing viruses in suspensions by copper oxide-based filters. Antimicrob Agents Chemother (2007) 0.90
Viral regulation of aquaporin 4, connexin 43, microcephalin and nucleolin. Schizophr Res (2007) 0.90
West Nile virus infection of the placenta. Virology (2006) 0.87
An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus. J Med Chem (2003) 0.86
Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids (2004) 0.85
Correlation between breakdown of the blood-brain barrier and disease outcome of viral encephalitis in mice. Antiviral Res (2006) 0.85
Prophylactic and therapeutic intervention of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with interferon alfacon-1. Antiviral Res (2008) 0.85
Treatment of lethal cowpox virus respiratory infections in mice with 2-amino-7-[(1,3-dihydroxy-2-propoxy)methyl]purine and its orally active diacetate ester prodrug. Antiviral Res (2002) 0.84
Protective immunity against Toxoplasma challenge in mice by coadministration of T. gondii antigens and Eimeria profilin-like protein as an adjuvant. Vaccine (2009) 0.83
Broad-spectrum inhibitor of viruses in the Flaviviridae family. Antiviral Res (2005) 0.83
Immunoprophylaxis of Punta Toro virus (Phlebovirus, Bunyaviridae) infection in hamsters with recombinant Eimeria profilin-like antigen. Int Immunopharmacol (2008) 0.83
Effect of oral gavage treatment with ZnAL42 and other metallo-ion formulations on influenza A H5N1 and H1N1 virus infections in mice. Antivir Chem Chemother (2007) 0.82
Treatment of mannan-enhanced influenza B virus infections in mice with oseltamivir, ribavirin and viramidine. Antivir Chem Chemother (2004) 0.82
Glial fibrillary acidic protein and glutamic acid decarboxylase 65 and 67 kDa proteins are increased in brains of neonatal BALB/c mice following viral infection in utero. Schizophr Res (2004) 0.82
in vitro inhibition of the measles virus by novel ring-expanded ('fat') nucleoside analogues containing the imidazo[4,5-e]diazepine ring system. Bioorg Med Chem Lett (2002) 0.78
Coumarins and pyranocoumarins, potential novel pharmacophores for inhibition of measles virus replication. Antivir Chem Chemother (2002) 0.77
Is the anti-psychotic, 10-(3-(dimethylamino)propyl)phenothiazine (promazine), a potential drug with which to treat SARS infections? Lack of efficacy of promazine on SARS-CoV replication in a mouse model. Antiviral Res (2008) 0.76
Potent in vitro activity of the albumin fusion type 1 interferons (albumin-interferon-alpha and albumin-interferon-beta) against RNA viral agents of bioterrorism and the severe acute respiratory syndrome (SARS) virus. Chemotherapy (2008) 0.76
Synthesis of N3,5'-cyclo-4-(beta-D-ribofuranosyl)-vic-triazolo[4,5-b]pyridin-5-one, a novel compound with anti-hepatitis C virus activity. J Med Chem (2004) 0.76
Antiviral activity of nucleoside analogues against SARS-coronavirus (SARS-coV). Antivir Chem Chemother (2006) 0.75